TRV250 is being developed for the acute treatment of migraine.Learn More
OLINVYK™ is approved by the FDA. Please see Important Safety Information including Boxed Warning in the full prescribing information available at OLINVYK.com. Additional pipeline assets are in development for migraine, opioid use disorder and other CNS indications as well as acute lung injury / acute respiratory distress syndrome (COVID-19). All of the company’s investigational assets have unique mechanisms of action (MOA) that are designed to optimize receptor pharmacology. The result is a pipeline of innovative therapies targeting well-known receptors, but with a potentially more favorable pharmacological profile than current drugs targeting the same receptor class.
|Program||Molecular Target||Therapeutic Target||Current Phase||PC||PH1||PH2||PH3||NDA||Now Approved|
|OLINVYK™ (oliceridine) injection||Mu receptor||Acute pain||Now Approved||Intravenous PC complete||PH1 complete||PH2 complete||PH3 complete||NDA complete||Now Approved in progress|
|TRV027||AT1 receptor||ARDS / abnormal clotting (COVID-19)||PH1||Intravenous PC complete||PH1 in progress||PH2 not started||PH3 not started||NDA not started||Now Approved not started|
|TRV250||Delta receptor||Acute migraine||PH1||Oral/Subcutaneous PC complete||PH1 in progress||PH2 not started||PH3 not started||NDA not started||Now Approved not started|
|TRV734||Mu receptor||Opioid use disorder||PH1||Oral PC complete||PH1 in progress||PH2 not started||PH3 not started||NDA not started||Now Approved not started|
|TRV045||S1P receptor||CNS disorders||PC||Oral PC in progress||PH1 not started||PH2 not started||PH3 not started||NDA not started||Now Approved not started|
G protein-coupled receptors (GPCRs) make up the largest family of transmembrane receptors, with approximately 34% of all U.S. Food and Drug Administration (FDA) approved drugs targeting this receptor class.
Typically, GPCR activation engages broad networks of signaling pathways, which are linked to distinct biological responses. Trevena’s compounds employ a functionally-selective MOA at the receptor site, which enables preferential activation of specific signaling pathways while minimizing activation of others.
Through this approach, the company believes it has developed a set of drug candidates with the potential to engage the signaling pathways responsible for therapeutic effect, with reduced activation of the pathways responsible for adverse effects, thus allowing for a more targeted approach to delivering therapeutic benefit.